BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 26679651)

  • 1. [Correlation between the level of the urinary 11-dehydrothromboxane B2 and the clinical efficacy of aspirin in patients with type 2 diabetes and coronary artery disease].
    Liu TF; Zhang JW; Chen XH; Feng XR; Bai ZS; Liu ML
    Beijing Da Xue Xue Bao Yi Xue Ban; 2015 Dec; 47(6):920-4. PubMed ID: 26679651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between urinary 11-dehydrothromboxane B2 detection and platelet Light Transmission Aggregometry (LTA) assays for evaluating aspirin response in elderly patients with coronary artery disease.
    Liu T; Zhang J; Chen X; Feng X; Fu SW; McCaffrey TA; Liu M
    Gene; 2015 Oct; 571(1):23-7. PubMed ID: 26095809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of urinary 11-dehydro-thromboxane B
    Vasudevan A; Tecson KM; Bennett-Firmin J; Bottiglieri T; Lopez LR; Peterson M; Sathyamoorthy M; Schiffmann R; Schussler JM; Swift C; Velasco CE; McCullough PA
    Catheter Cardiovasc Interv; 2018 Oct; 92(4):653-658. PubMed ID: 29193683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Residual thromboxane activity and oxidative stress: influence on mortality in patients with stable coronary artery disease.
    Vasudevan A; Bottiglieri T; Tecson KM; Sathyamoorthy M; Schussler JM; Velasco CE; Lopez LR; Swift C; Peterson M; Bennett-Firmin J; Schiffmann R; McCullough PA
    Coron Artery Dis; 2017 Jun; 28(4):287-293. PubMed ID: 28005558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary 11-Dehydro-Thromboxane B
    McCullough PA; Vasudevan A; Sathyamoorthy M; Schussler JM; Velasco CE; Lopez LR; Swift C; Peterson M; Bennett-Firmin J; Schiffmann R; Bottiglieri T
    Am J Cardiol; 2017 Apr; 119(7):972-977. PubMed ID: 28139223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin?
    Markuszewski L; Rosiak M; Golanski J; Rysz J; Spychalska M; Watala C
    Basic Clin Pharmacol Toxicol; 2006 May; 98(5):503-9. PubMed ID: 16635110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes.
    Christensen KH; Grove EL; Würtz M; Kristensen SD; Hvas AM
    Platelets; 2015; 26(3):230-5. PubMed ID: 24750015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of polymorphism and type II diabetes on aspirin resistance in patients with unstable coronary artery disease.
    Gao F; Wang ZX; Men JL; Ren J; Wei MX
    Chin Med J (Engl); 2011 Jun; 124(11):1731-4. PubMed ID: 21740787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspirin resistance in Indian patients with coronary artery disease and cardiovascular events.
    Thomson VS; John B; George P; Joseph G; Jose J
    J Postgrad Med; 2009; 55(4):252-6. PubMed ID: 20083870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin.
    Bliden KP; Singla A; Gesheff MG; Toth PP; Tabrizchi A; Ens G; Guyer K; Singh M; Franzese CJ; Stapleton D; Tantry US; Gurbel PA
    Thromb Haemost; 2014 Aug; 112(2):323-31. PubMed ID: 24763965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease.
    Larsen SB; Grove EL; Kristensen SD; Hvas AM
    Thromb Haemost; 2013 May; 109(5):920-9. PubMed ID: 23407706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study.
    Karolczak K; Kamysz W; Karafova A; Drzewoski J; Watala C
    Pharmacol Res; 2013 Aug; 74():7-22. PubMed ID: 23665469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of aspirin response measured by urinary 11-dehydrothromboxane B2 and VerifyNow aspirin assay in patients with ischemic stroke.
    Dharmasaroja PA; Sae-Lim S
    J Stroke Cerebrovasc Dis; 2014; 23(5):953-7. PubMed ID: 24126290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arachidonic acid-stimulated platelet tests: Identification of patients less sensitive to aspirin treatment.
    Temperilli F; Rina A; Massimi I; Montemari AL; Guarino ML; Zicari A; Pulcinelli FM
    Platelets; 2015; 26(8):783-7. PubMed ID: 25734355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Association between CMTM5 gene rs723840 single nucleotide polymorphism and high on asprin platelet reactivity].
    Liu TF; Zhang JW; Chen XH; Feng XR; Bai ZS; Liu ML
    Beijing Da Xue Xue Bao Yi Xue Ban; 2015 Dec; 47(6):905-9. PubMed ID: 26679648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response variability to aspirin and one-year prediction of vascular events in patients with stable coronary artery disease.
    Addad F; Chakroun T; Abderazek F; Ben-Farhat M; Hamdi S; Dridi Z; Gamra H; Hassine M; Samama MM; Elalamy I
    J Thromb Thrombolysis; 2010 Jan; 29(1):108-13. PubMed ID: 19381450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of plasma concentrations of salicylic acid and high on ASA platelet reactivity in type 2 diabetes patients.
    Postula M; Janicki PK; Rosiak M; Przybylkowski A; Kaplon-Cieslicka A; Grygorowicz T; Trzepla E; Filipiak KJ; Czlonkowski A; Opolski G
    Cardiol J; 2013; 20(2):170-7. PubMed ID: 23558875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Association between Multi-Vessel Coronary Artery Disease and High On-Aspirin Platelet Reactivity.
    Shiyovich A; Sasson L; Lev E; Solodky A; Kornowski R; Perl L
    Cardiovasc Drugs Ther; 2022 Jun; 36(3):449-454. PubMed ID: 33988836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of high platelet reactivity during aspirin treatment in patients with type 2 diabetes.
    Kapłon-Cieślicka A; Rosiak M; Postuła M; Serafin A; Kondracka A; Opolski G; Filipiak KJ
    Kardiol Pol; 2013; 71(9):893-902. PubMed ID: 24065375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet thromboxane (11-dehydro-Thromboxane B2) and aspirin response in patients with diabetes and coronary artery disease.
    Lopez LR; Guyer KE; Torre IG; Pitts KR; Matsuura E; Ames PR
    World J Diabetes; 2014 Apr; 5(2):115-27. PubMed ID: 24748925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.